CTS guidelines on the submission of clinical trials for COVID-19

Web conference "Theft of medicines - Analysis and trends of a complex phenomenon"

EMA starts rolling review of Janssen’s COVID-19 vaccine Ad26.COV2.S

EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine

EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2

Norme di igiene e di distanziamento fisico per l’esecuzione delle ispezioni on-site eseguite dall’Ufficio Ispezioni e Autorizzazioni GMP Medicinali

Italian Medicines Agency's Communiction to CRFV / RLFV on the management of reporting adverse reactions to medicines used in COVID-19 therapy - UPDATE

COVID-19: AIFA limits the use of remdesivir in selected cases and allows for hydroxychloroquine to be used only in randomised clinical trials in an outpatient setting

Update on remdesivir - EMA will evaluate new data from Solidarity trial

Vaccines: “Wrong to spread unfounded claims on safety”, Magrini says

AIFA’s Scientific-technical committee to reassess remdesivir in anti Covid-19 therapy

EMA considerations on Covid-19 vaccine approval

Web conference "The cooperation between Regions, Autonomous Provinces, AIFA and companies against COVID shortages"

Updates on oxygen distribution (18 November 2020)

EMA starts rolling review of mRNA COVID-19 vaccine by Moderna Biotech Spain, S.L.

Aggiornamenti in merito alla disponibilità di ossigeno medicinale

COVID-19: dichiarazione congiunta OMS - ICMRA

Aggiornamento della procedura di richiesta per il farmaco Veklury® (remdesivir)

Attivazione Registro VEKLURY (remdesivir)

AIFA firma appello "Nature" - Un network europeo di agenzie nazionali per la risposta all'emergenza COVID-19 e ad altre epidemie